NCT07227857招募中1 期
A Phase Ib/II First-in-human, Multicentre, Open-label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effect of Intrathecal S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 21
- 主要终点
- Incidence and severity of Adverse Events (AE)'s.
研究概览
简要总结
Study CL1-230815-001 (KANDLE) is a Phase Ib/II, First In Human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effect of S230815 in pediatric participants with KCNT1-related Developmental Epileptic Encephalopathy. To participate in the study, participants must have a diagnosis of Developmental Epileptic Encephalopathy due to a documented pathogenic or likely pathogenic variant in KCNT1 (to be confirmed by central genetic testing at the screening visit). The study consists of a screening period followed by two consecutive interventional parts. Part 1 will evaluate multiple ascending doses of S230815. Part 2 is a long-term treatment extension for participants who have completed Part 1. Participants will seamlessly roll-over from Part 1 to Part 2, resuming the same cohort as they were assigned in Part 1, and will receive S230815 for a maximum of 72 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female pediatric participants aged 2-12 years old at screening, with a genetically confirmed diagnosis of Developmental Epileptic Encephalopathy (DEE) due to a pathogenic or likely pathogenic variant in KCNT1 confirmed by central genetic testing.
- •Stable dose of other regular medications and/or stable antiseizure interventions (such as ketogenic diet and vagal nerve stimulation).
排除标准
- •Other clinical phenotypes associated with pathogenic or likely pathogenic variants in KCNT1 other than Epilepsy of Infancy with Migrating Focal Seizures or Early-Onset Epileptic Encephalopathy
- •Documented pathogenic or likely pathogenic variants in any other gene known to cause epilepsy identified through prior genetic testing. Variants of uncertain significance in other genes known to cause epilepsy may be considered on discussion with the sponsor.
- •Clinically significant medical history or clinical findings on physical examination, other than DEE, that in the judgment of the investigator, make the participant unsuitable for participation in the study and/or completion of the trial procedures, including, but not limited to:
- •Clinically significant prior or ongoing medical conditions within 30 days of the screening visit, as per investigator judgement.
- •Clinically significant abnormality on Electrocardiogram (ECG) at the screening visit, as per investigator judgement.
- •Clinically significant abnormality on laboratory testing at screening, including, but not limited to:
- •Renal insufficiency, which is defined as creatinine clearance < 40 mL/min assessed as estimated glomerular filtration rate (eGFR) using Modification of Diet in Renal Disease (MDRD) formula
- •Hepatic derangement defined as transaminase values more than 3 times the Upper Limit of Normal (ULN) range, or total bilirubin values more than 1.5 times the ULN.
- •Positive hepatitis B surface antigen test, positive hepatitis C antibody test, positive for human immunodeficiency virus (HIV), as reported by a laboratory test within 6 months prior to the screening visit, or on screening bloods.
- •Bone, spine, bleeding disorders, or other disorder that exposes the participant to risk of injury or unsuccessful Lumbar puncture (e.g., haemophilia, Von Willebrand's disease, liver disease).
- •Contraindications to undergoing Magnetic Resonance Imaging (MRI), Lumbar puncture procedure and Intrathecal administration.
- •History of Central Nervous System (CNS) tumors or malignancies, including CNS metastatic disease.
- •Continuous respiratory support, defined as oxygen supplementation or non-invasive ventilation (e.g.: continuous positive airway pressure, bi-level intermittent positive airway pressure), required during waking hours. This does not include suctioning; cough assist devices or other devices that may be used regularly to clear airways.
- •Invasive ventilation including the presence of a tracheostomy.
- •Use of quinidine within 30 days prior to the screening visit.
- •Current use or anticipated use of antiplatelet or anticoagulant therapy during the study.
- •Current or past enrolment in an interventional clinical study in which an investigational therapy is/was administered within 30 days (or 5 half-lives of study agent, whichever is longer) prior to the screening visit.
- •Implantable CNS device that may interfere with the ability to administer the study drug via Lumbar puncture.
- •Known hypersensitivity to any oligonucleotide, as demonstrated by a systemic allergic reaction (e.g., changes in pulse, blood pressure, breathing function, etc.), or any other drug that in the opinion of the investigator may preclude study participation.
- •History of hydrocephalus requiring a ventriculoperitoneal shunt.
研究组 & 干预措施
Cohort 1
Experimental
干预措施: S230815- Starting dose A (Drug)
Cohort 2
Experimental
干预措施: S230815- Dose B (Drug)
Cohort 3
Experimental
干预措施: S230815- Dose C (Drug)
Cohort 4
Experimental
干预措施: S230815- Dose D (Drug)
结局指标
主要结局
Incidence and severity of Adverse Events (AE)'s.
时间窗: Through End of study visit (A maximum of 116 weeks)
次要结局
- Pharmacokinetic (PK) parameters of S230815 in cerebrospinal fluid (CSF) Ctrough(Through week 96)
- Pharmacokinetic (PK) parameters of S230815 in plasma AUC 0-τ(Through End of study visit (A maximum of 116 weeks))
- Pharmacokinetic (PK) parameters of S230815 in plasma Cmax(Through End of study visit (A maximum of 116 weeks))
- Pharmacokinetic (PK) parameters of S230815 in plasma Ctrough(Through End of study visit (A maximum of 116 weeks))
- Relative change from baseline in seizure frequency as recorded by daily seizure logs(Through End of study visit (A maximum of 116 weeks))
- Relative change from baseline in seizure frequency as recorded by periodic 24h Video Electroencephalogram (vEEG) assessment(Through End of study visit (A maximum of 116 weeks))
- Number and administration frequency of rescue medication(Through End of study visit (A maximum of 116 weeks))
研究者
研究点 (21)
Loading locations...
相似试验
尚未招募
1 期
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.NCT06928363Novatim Immune Therapeutics (Zhejiang) Co., Ltd.212
终止
1 期
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT05427812Ichnos Sciences SA29
招募中
1 期
XTX301 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05684965Xilio Development, Inc.358
已完成
1 期
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsAdvanced Solid TumorNCT04896697Xilio Development, Inc.125
招募中
1 期
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849Advanced Solid TumorNCT057612231ST Biotherapeutics, Inc.151